Application of Fragment-Based Lead Generation to the Discovery of Novel, Cyclic Amidine β-Secretase Inhibitors with Nanomolar Potency, Cellular Activity, and High Ligand Efficiency

Fragment-based lead generation has led to the discovery of a novel series of cyclic amidine-based inhibitors of β-secretase (BACE-1). Initial fragment hits with an isocytosine core having millimolar potency were identified via NMR affinity screening. Structure-guided evolution of these fragments usi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 2007-11, Vol.50 (24), p.5912-5925
Hauptverfasser: Edwards, Philip D, Albert, Jeffrey S, Sylvester, Mark, Aharony, David, Andisik, Donald, Callaghan, Owen, Campbell, James B, Carr, Robin A, Chessari, Gianni, Congreve, Miles, Frederickson, Martyn, Folmer, Rutger H. A, Geschwindner, Stefan, Koether, Gerard, Kolmodin, Karin, Krumrine, Jennifer, Mauger, Russell C, Murray, Christopher W, Olsson, Lise-Lotte, Patel, Sahil, Spear, Nate, Tian, Gaochao
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 5925
container_issue 24
container_start_page 5912
container_title Journal of medicinal chemistry
container_volume 50
creator Edwards, Philip D
Albert, Jeffrey S
Sylvester, Mark
Aharony, David
Andisik, Donald
Callaghan, Owen
Campbell, James B
Carr, Robin A
Chessari, Gianni
Congreve, Miles
Frederickson, Martyn
Folmer, Rutger H. A
Geschwindner, Stefan
Koether, Gerard
Kolmodin, Karin
Krumrine, Jennifer
Mauger, Russell C
Murray, Christopher W
Olsson, Lise-Lotte
Patel, Sahil
Spear, Nate
Tian, Gaochao
description Fragment-based lead generation has led to the discovery of a novel series of cyclic amidine-based inhibitors of β-secretase (BACE-1). Initial fragment hits with an isocytosine core having millimolar potency were identified via NMR affinity screening. Structure-guided evolution of these fragments using X-ray crystallography together with potency determination using surface plasmon resonance and functional enzyme inhibition assays afforded micromolar inhibitors. Similarity searching around the isocytosine core led to the identification of a related series of inhibitors, the dihydroisocytosines. By leveraging the knowledge of the ligand-BACE-1 recognition features generated from the isocytosines, the dihydroisocytosines were efficiently optimized to submicromolar potency. Compound 29, with an IC50 of 80 nM, a ligand efficiency of 0.37, and cellular activity of 470 nM, emerged as the lead structure for future optimization.
doi_str_mv 10.1021/jm070829p
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68543259</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68543259</sourcerecordid><originalsourceid>FETCH-LOGICAL-a381t-bccb6000d32ab302e274e5ab00ef6e33840baef3c4186bde6b47e4ef2c4dc8e13</originalsourceid><addsrcrecordid>eNptkc2O0zAQxy0EYsvCgRdAvrASEgHHzod77HY_UVkqbRFHy3EmrUtiB9tZ6Gsh8Ro8E45abS-cZjTzm79m5o_Q65R8SAlNP247UhJOp_0TNElzSpKMk-wpmhBCaUILyk7QC--3hBCWUvYcnaTllOe8oBP0Z9b3rVYyaGuwbfCVk-sOTEjOpYcaL0DW-BoMuD0RLA4bwBfaK_sAbjeO3MWsfY_nOxWF8KzTtTaA__5O7kE5CFEH35qNrnSwzuOfOmzwnTS2s610eGkDGLWL49C2w1iZqaAfdIglaWp8o9cbvNDrMb9sGq30iL9EzxrZenh1iKfo69Xlan6TLL5c385ni0QynoakUqoq4tU1o7JihAItM8hlRQg0BTDGM1JJaJjKUl5UNRRVVkIGDVVZrTik7BSd7XV7Z38M4IPo4uVxU2nADl4UPM8YzacRfLcHlbPeO2hE73Qn3U6kRIweiUePIvvmIDpUHdRH8mBKBN4eAOmVbBsnjdL-yE05J6TkkUv2nPYBfj32pfsuipKVuVgt78Xq0-eL_Nv5UiyOulJ5sbWDM_F3_1nwHxEbuFA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68543259</pqid></control><display><type>article</type><title>Application of Fragment-Based Lead Generation to the Discovery of Novel, Cyclic Amidine β-Secretase Inhibitors with Nanomolar Potency, Cellular Activity, and High Ligand Efficiency</title><source>ACS Publications</source><source>MEDLINE</source><creator>Edwards, Philip D ; Albert, Jeffrey S ; Sylvester, Mark ; Aharony, David ; Andisik, Donald ; Callaghan, Owen ; Campbell, James B ; Carr, Robin A ; Chessari, Gianni ; Congreve, Miles ; Frederickson, Martyn ; Folmer, Rutger H. A ; Geschwindner, Stefan ; Koether, Gerard ; Kolmodin, Karin ; Krumrine, Jennifer ; Mauger, Russell C ; Murray, Christopher W ; Olsson, Lise-Lotte ; Patel, Sahil ; Spear, Nate ; Tian, Gaochao</creator><creatorcontrib>Edwards, Philip D ; Albert, Jeffrey S ; Sylvester, Mark ; Aharony, David ; Andisik, Donald ; Callaghan, Owen ; Campbell, James B ; Carr, Robin A ; Chessari, Gianni ; Congreve, Miles ; Frederickson, Martyn ; Folmer, Rutger H. A ; Geschwindner, Stefan ; Koether, Gerard ; Kolmodin, Karin ; Krumrine, Jennifer ; Mauger, Russell C ; Murray, Christopher W ; Olsson, Lise-Lotte ; Patel, Sahil ; Spear, Nate ; Tian, Gaochao</creatorcontrib><description>Fragment-based lead generation has led to the discovery of a novel series of cyclic amidine-based inhibitors of β-secretase (BACE-1). Initial fragment hits with an isocytosine core having millimolar potency were identified via NMR affinity screening. Structure-guided evolution of these fragments using X-ray crystallography together with potency determination using surface plasmon resonance and functional enzyme inhibition assays afforded micromolar inhibitors. Similarity searching around the isocytosine core led to the identification of a related series of inhibitors, the dihydroisocytosines. By leveraging the knowledge of the ligand-BACE-1 recognition features generated from the isocytosines, the dihydroisocytosines were efficiently optimized to submicromolar potency. Compound 29, with an IC50 of 80 nM, a ligand efficiency of 0.37, and cellular activity of 470 nM, emerged as the lead structure for future optimization.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm070829p</identifier><identifier>PMID: 17985862</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Washington, DC: American Chemical Society</publisher><subject>Amidines - chemical synthesis ; Amidines - chemistry ; Amidines - pharmacology ; Amyloid Precursor Protein Secretases - antagonists &amp; inhibitors ; Amyloid Precursor Protein Secretases - chemistry ; Amyloid Precursor Protein Secretases - genetics ; Aspartic Acid Endopeptidases - antagonists &amp; inhibitors ; Aspartic Acid Endopeptidases - chemistry ; Aspartic Acid Endopeptidases - genetics ; Biological and medical sciences ; Cell Line ; Crystallography, X-Ray ; Cytosine - analogs &amp; derivatives ; Cytosine - chemical synthesis ; Cytosine - chemistry ; Cytosine - pharmacology ; Fluorescence Resonance Energy Transfer ; Humans ; Ligands ; Magnetic Resonance Spectroscopy ; Medical sciences ; Models, Molecular ; Neuropharmacology ; Pharmacology. Drug treatments ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Pyrimidines - chemical synthesis ; Pyrimidines - chemistry ; Pyrimidines - pharmacology ; Stereoisomerism ; Structure-Activity Relationship</subject><ispartof>Journal of medicinal chemistry, 2007-11, Vol.50 (24), p.5912-5925</ispartof><rights>Copyright © 2007 American Chemical Society</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a381t-bccb6000d32ab302e274e5ab00ef6e33840baef3c4186bde6b47e4ef2c4dc8e13</citedby><cites>FETCH-LOGICAL-a381t-bccb6000d32ab302e274e5ab00ef6e33840baef3c4186bde6b47e4ef2c4dc8e13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm070829p$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm070829p$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,2752,27053,27901,27902,56713,56763</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=19880078$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17985862$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Edwards, Philip D</creatorcontrib><creatorcontrib>Albert, Jeffrey S</creatorcontrib><creatorcontrib>Sylvester, Mark</creatorcontrib><creatorcontrib>Aharony, David</creatorcontrib><creatorcontrib>Andisik, Donald</creatorcontrib><creatorcontrib>Callaghan, Owen</creatorcontrib><creatorcontrib>Campbell, James B</creatorcontrib><creatorcontrib>Carr, Robin A</creatorcontrib><creatorcontrib>Chessari, Gianni</creatorcontrib><creatorcontrib>Congreve, Miles</creatorcontrib><creatorcontrib>Frederickson, Martyn</creatorcontrib><creatorcontrib>Folmer, Rutger H. A</creatorcontrib><creatorcontrib>Geschwindner, Stefan</creatorcontrib><creatorcontrib>Koether, Gerard</creatorcontrib><creatorcontrib>Kolmodin, Karin</creatorcontrib><creatorcontrib>Krumrine, Jennifer</creatorcontrib><creatorcontrib>Mauger, Russell C</creatorcontrib><creatorcontrib>Murray, Christopher W</creatorcontrib><creatorcontrib>Olsson, Lise-Lotte</creatorcontrib><creatorcontrib>Patel, Sahil</creatorcontrib><creatorcontrib>Spear, Nate</creatorcontrib><creatorcontrib>Tian, Gaochao</creatorcontrib><title>Application of Fragment-Based Lead Generation to the Discovery of Novel, Cyclic Amidine β-Secretase Inhibitors with Nanomolar Potency, Cellular Activity, and High Ligand Efficiency</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>Fragment-based lead generation has led to the discovery of a novel series of cyclic amidine-based inhibitors of β-secretase (BACE-1). Initial fragment hits with an isocytosine core having millimolar potency were identified via NMR affinity screening. Structure-guided evolution of these fragments using X-ray crystallography together with potency determination using surface plasmon resonance and functional enzyme inhibition assays afforded micromolar inhibitors. Similarity searching around the isocytosine core led to the identification of a related series of inhibitors, the dihydroisocytosines. By leveraging the knowledge of the ligand-BACE-1 recognition features generated from the isocytosines, the dihydroisocytosines were efficiently optimized to submicromolar potency. Compound 29, with an IC50 of 80 nM, a ligand efficiency of 0.37, and cellular activity of 470 nM, emerged as the lead structure for future optimization.</description><subject>Amidines - chemical synthesis</subject><subject>Amidines - chemistry</subject><subject>Amidines - pharmacology</subject><subject>Amyloid Precursor Protein Secretases - antagonists &amp; inhibitors</subject><subject>Amyloid Precursor Protein Secretases - chemistry</subject><subject>Amyloid Precursor Protein Secretases - genetics</subject><subject>Aspartic Acid Endopeptidases - antagonists &amp; inhibitors</subject><subject>Aspartic Acid Endopeptidases - chemistry</subject><subject>Aspartic Acid Endopeptidases - genetics</subject><subject>Biological and medical sciences</subject><subject>Cell Line</subject><subject>Crystallography, X-Ray</subject><subject>Cytosine - analogs &amp; derivatives</subject><subject>Cytosine - chemical synthesis</subject><subject>Cytosine - chemistry</subject><subject>Cytosine - pharmacology</subject><subject>Fluorescence Resonance Energy Transfer</subject><subject>Humans</subject><subject>Ligands</subject><subject>Magnetic Resonance Spectroscopy</subject><subject>Medical sciences</subject><subject>Models, Molecular</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Pyrimidines - chemical synthesis</subject><subject>Pyrimidines - chemistry</subject><subject>Pyrimidines - pharmacology</subject><subject>Stereoisomerism</subject><subject>Structure-Activity Relationship</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkc2O0zAQxy0EYsvCgRdAvrASEgHHzod77HY_UVkqbRFHy3EmrUtiB9tZ6Gsh8Ro8E45abS-cZjTzm79m5o_Q65R8SAlNP247UhJOp_0TNElzSpKMk-wpmhBCaUILyk7QC--3hBCWUvYcnaTllOe8oBP0Z9b3rVYyaGuwbfCVk-sOTEjOpYcaL0DW-BoMuD0RLA4bwBfaK_sAbjeO3MWsfY_nOxWF8KzTtTaA__5O7kE5CFEH35qNrnSwzuOfOmzwnTS2s610eGkDGLWL49C2w1iZqaAfdIglaWp8o9cbvNDrMb9sGq30iL9EzxrZenh1iKfo69Xlan6TLL5c385ni0QynoakUqoq4tU1o7JihAItM8hlRQg0BTDGM1JJaJjKUl5UNRRVVkIGDVVZrTik7BSd7XV7Z38M4IPo4uVxU2nADl4UPM8YzacRfLcHlbPeO2hE73Qn3U6kRIweiUePIvvmIDpUHdRH8mBKBN4eAOmVbBsnjdL-yE05J6TkkUv2nPYBfj32pfsuipKVuVgt78Xq0-eL_Nv5UiyOulJ5sbWDM_F3_1nwHxEbuFA</recordid><startdate>20071129</startdate><enddate>20071129</enddate><creator>Edwards, Philip D</creator><creator>Albert, Jeffrey S</creator><creator>Sylvester, Mark</creator><creator>Aharony, David</creator><creator>Andisik, Donald</creator><creator>Callaghan, Owen</creator><creator>Campbell, James B</creator><creator>Carr, Robin A</creator><creator>Chessari, Gianni</creator><creator>Congreve, Miles</creator><creator>Frederickson, Martyn</creator><creator>Folmer, Rutger H. A</creator><creator>Geschwindner, Stefan</creator><creator>Koether, Gerard</creator><creator>Kolmodin, Karin</creator><creator>Krumrine, Jennifer</creator><creator>Mauger, Russell C</creator><creator>Murray, Christopher W</creator><creator>Olsson, Lise-Lotte</creator><creator>Patel, Sahil</creator><creator>Spear, Nate</creator><creator>Tian, Gaochao</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20071129</creationdate><title>Application of Fragment-Based Lead Generation to the Discovery of Novel, Cyclic Amidine β-Secretase Inhibitors with Nanomolar Potency, Cellular Activity, and High Ligand Efficiency</title><author>Edwards, Philip D ; Albert, Jeffrey S ; Sylvester, Mark ; Aharony, David ; Andisik, Donald ; Callaghan, Owen ; Campbell, James B ; Carr, Robin A ; Chessari, Gianni ; Congreve, Miles ; Frederickson, Martyn ; Folmer, Rutger H. A ; Geschwindner, Stefan ; Koether, Gerard ; Kolmodin, Karin ; Krumrine, Jennifer ; Mauger, Russell C ; Murray, Christopher W ; Olsson, Lise-Lotte ; Patel, Sahil ; Spear, Nate ; Tian, Gaochao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a381t-bccb6000d32ab302e274e5ab00ef6e33840baef3c4186bde6b47e4ef2c4dc8e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Amidines - chemical synthesis</topic><topic>Amidines - chemistry</topic><topic>Amidines - pharmacology</topic><topic>Amyloid Precursor Protein Secretases - antagonists &amp; inhibitors</topic><topic>Amyloid Precursor Protein Secretases - chemistry</topic><topic>Amyloid Precursor Protein Secretases - genetics</topic><topic>Aspartic Acid Endopeptidases - antagonists &amp; inhibitors</topic><topic>Aspartic Acid Endopeptidases - chemistry</topic><topic>Aspartic Acid Endopeptidases - genetics</topic><topic>Biological and medical sciences</topic><topic>Cell Line</topic><topic>Crystallography, X-Ray</topic><topic>Cytosine - analogs &amp; derivatives</topic><topic>Cytosine - chemical synthesis</topic><topic>Cytosine - chemistry</topic><topic>Cytosine - pharmacology</topic><topic>Fluorescence Resonance Energy Transfer</topic><topic>Humans</topic><topic>Ligands</topic><topic>Magnetic Resonance Spectroscopy</topic><topic>Medical sciences</topic><topic>Models, Molecular</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Pyrimidines - chemical synthesis</topic><topic>Pyrimidines - chemistry</topic><topic>Pyrimidines - pharmacology</topic><topic>Stereoisomerism</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Edwards, Philip D</creatorcontrib><creatorcontrib>Albert, Jeffrey S</creatorcontrib><creatorcontrib>Sylvester, Mark</creatorcontrib><creatorcontrib>Aharony, David</creatorcontrib><creatorcontrib>Andisik, Donald</creatorcontrib><creatorcontrib>Callaghan, Owen</creatorcontrib><creatorcontrib>Campbell, James B</creatorcontrib><creatorcontrib>Carr, Robin A</creatorcontrib><creatorcontrib>Chessari, Gianni</creatorcontrib><creatorcontrib>Congreve, Miles</creatorcontrib><creatorcontrib>Frederickson, Martyn</creatorcontrib><creatorcontrib>Folmer, Rutger H. A</creatorcontrib><creatorcontrib>Geschwindner, Stefan</creatorcontrib><creatorcontrib>Koether, Gerard</creatorcontrib><creatorcontrib>Kolmodin, Karin</creatorcontrib><creatorcontrib>Krumrine, Jennifer</creatorcontrib><creatorcontrib>Mauger, Russell C</creatorcontrib><creatorcontrib>Murray, Christopher W</creatorcontrib><creatorcontrib>Olsson, Lise-Lotte</creatorcontrib><creatorcontrib>Patel, Sahil</creatorcontrib><creatorcontrib>Spear, Nate</creatorcontrib><creatorcontrib>Tian, Gaochao</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Edwards, Philip D</au><au>Albert, Jeffrey S</au><au>Sylvester, Mark</au><au>Aharony, David</au><au>Andisik, Donald</au><au>Callaghan, Owen</au><au>Campbell, James B</au><au>Carr, Robin A</au><au>Chessari, Gianni</au><au>Congreve, Miles</au><au>Frederickson, Martyn</au><au>Folmer, Rutger H. A</au><au>Geschwindner, Stefan</au><au>Koether, Gerard</au><au>Kolmodin, Karin</au><au>Krumrine, Jennifer</au><au>Mauger, Russell C</au><au>Murray, Christopher W</au><au>Olsson, Lise-Lotte</au><au>Patel, Sahil</au><au>Spear, Nate</au><au>Tian, Gaochao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Application of Fragment-Based Lead Generation to the Discovery of Novel, Cyclic Amidine β-Secretase Inhibitors with Nanomolar Potency, Cellular Activity, and High Ligand Efficiency</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2007-11-29</date><risdate>2007</risdate><volume>50</volume><issue>24</issue><spage>5912</spage><epage>5925</epage><pages>5912-5925</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>Fragment-based lead generation has led to the discovery of a novel series of cyclic amidine-based inhibitors of β-secretase (BACE-1). Initial fragment hits with an isocytosine core having millimolar potency were identified via NMR affinity screening. Structure-guided evolution of these fragments using X-ray crystallography together with potency determination using surface plasmon resonance and functional enzyme inhibition assays afforded micromolar inhibitors. Similarity searching around the isocytosine core led to the identification of a related series of inhibitors, the dihydroisocytosines. By leveraging the knowledge of the ligand-BACE-1 recognition features generated from the isocytosines, the dihydroisocytosines were efficiently optimized to submicromolar potency. Compound 29, with an IC50 of 80 nM, a ligand efficiency of 0.37, and cellular activity of 470 nM, emerged as the lead structure for future optimization.</abstract><cop>Washington, DC</cop><pub>American Chemical Society</pub><pmid>17985862</pmid><doi>10.1021/jm070829p</doi><tpages>14</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 2007-11, Vol.50 (24), p.5912-5925
issn 0022-2623
1520-4804
language eng
recordid cdi_proquest_miscellaneous_68543259
source ACS Publications; MEDLINE
subjects Amidines - chemical synthesis
Amidines - chemistry
Amidines - pharmacology
Amyloid Precursor Protein Secretases - antagonists & inhibitors
Amyloid Precursor Protein Secretases - chemistry
Amyloid Precursor Protein Secretases - genetics
Aspartic Acid Endopeptidases - antagonists & inhibitors
Aspartic Acid Endopeptidases - chemistry
Aspartic Acid Endopeptidases - genetics
Biological and medical sciences
Cell Line
Crystallography, X-Ray
Cytosine - analogs & derivatives
Cytosine - chemical synthesis
Cytosine - chemistry
Cytosine - pharmacology
Fluorescence Resonance Energy Transfer
Humans
Ligands
Magnetic Resonance Spectroscopy
Medical sciences
Models, Molecular
Neuropharmacology
Pharmacology. Drug treatments
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Pyrimidines - chemical synthesis
Pyrimidines - chemistry
Pyrimidines - pharmacology
Stereoisomerism
Structure-Activity Relationship
title Application of Fragment-Based Lead Generation to the Discovery of Novel, Cyclic Amidine β-Secretase Inhibitors with Nanomolar Potency, Cellular Activity, and High Ligand Efficiency
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T04%3A52%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Application%20of%20Fragment-Based%20Lead%20Generation%20to%20the%20Discovery%20of%20Novel,%20Cyclic%20Amidine%20%CE%B2-Secretase%20Inhibitors%20with%20Nanomolar%20Potency,%20Cellular%20Activity,%20and%20High%20Ligand%20Efficiency&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Edwards,%20Philip%20D&rft.date=2007-11-29&rft.volume=50&rft.issue=24&rft.spage=5912&rft.epage=5925&rft.pages=5912-5925&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm070829p&rft_dat=%3Cproquest_cross%3E68543259%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68543259&rft_id=info:pmid/17985862&rfr_iscdi=true